Ponesimod is a selective sphingosine-1-phosphate (S1P)1 receptor agonist being developed by Johnson & Johnson specifically as a drug for relapsing-remitting multiple sclerosis (RRMS). It has a shared mechanism with Gilenya (fingolimod; Novartis/Mitsubishi Tanabe), with the class acting to reduce the overall number of circulating lymphocytes available to mount an autoimmune reaction to the myelin sheath surrounding axons in MS.
Johnson & Johnson added ponesimod to its pipeline upon its 2017 acquisition of Actelion for $30bn. Roche previously had a license to co-develop and commercialize ponesimod with Actelion, although this was discontinued in December 2009 after a portfolio review following Roche’s acquisition of Genentech. As such, Actelion progressed ponesimod through to its pivotal Phase III program by itself, and will now market the drug as part of Johnson & Johnson.
LIST OF FIGURES 7 Figure 1: Ponesimod for multiple sclerosis – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of ponesimod for multiple sclerosis
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of ponesimod for multiple sclerosis
11 Figure 4: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES 5 Table 1: Ponesimod drug profile
6 Table 2: Ponesimod Phase III trials in multiple sclerosis
12 Table 3: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.